Generation Bio (GBIO) Registration Filing summary

Company overview and business model

• Innovates non-viral genetic medicines for durable, redosable treatments targeting rare and prevalent diseases.

• Develops two platforms: a cell-targeted lipid nanoparticle (ctLNP) system for nucleic acid delivery and an immune-quiet DNA platform for long-lasting gene expression.

• Aims to address large patient populations with differentiated therapeutic applications.

Financial performance and metrics

• As of August 2, 2024, 66,741,175 shares of common stock were outstanding; no preferred stock was outstanding.

• The company’s common stock is listed on Nasdaq under the symbol “GBIO.”

• The closing price on August 6, 2024, was $2.45 per share.

Use of proceeds and capital allocation

• Net proceeds from securities sales will be used for general corporate purposes, including acquisitions, debt repayment, working capital, and capital expenditures.

• Proceeds from the at-the-market program may also fund research, clinical development, commercial efforts, and potential acquisitions or investments.

• Management retains broad discretion over allocation of proceeds.